Skip to main content
Clinical Trials/NL-OMON23089
NL-OMON23089
Recruiting
Not Applicable

Safety and pharmacokinetics of antipsychotics in children 2: Studying TDM in an RCT

Erasmus Medical Center Rotterdam0 sites140 target enrollmentTBD

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Autism Spectrum Disorder
Sponsor
Erasmus Medical Center Rotterdam
Enrollment
140
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional

Investigators

Sponsor
Erasmus Medical Center Rotterdam

Eligibility Criteria

Inclusion Criteria

  • Age 6 to 18 years
  • Documented clinical diagnosis of autism spectrum disorder according to DSM IV or DSM V and comorbid behavioural problems
  • To start treatment with risperidone

Exclusion Criteria

  • Diabetes type I or II
  • Congenital or acquired syndrome associated with changes in appetite, body weight or lipid profile (e.g. Prader Willi)
  • Treatment with antipsychotic medication within the last 6 months
  • Known Long QT syndrome (LQTS)

Outcomes

Primary Outcomes

Not specified

Similar Trials